FrancophonIA/ELRC3.0 huggingface dataset:
English: The 20 mg tablets can be used for reflux disease to treat symptoms such as heartburns and acid regurgitation (acid flowing up in the mouth), for the long-term management and prevention of relapse in reflux oesophagitis (inflammation of the gullet, due to acid), for the prevention of the stomach ulcers that can be caused by some medicines used to treat pain and inflammations called non-selective non-steroidal anti-inflammatory drugs (NSAIDs), when the patient needs continuous NSAID treatment.
Estonian: 20 mg tablette saab kasutada reflukshaiguse puhul sümptomite, näiteks kõrvetiste ja happe regurgitatsiooni (happe tagasivool maost söögitorru ja suhu) raviks, samuti refluksösofagiidi (happest tingitud söögitorupõletik) pikaajaliseks raviks ja relapsi profülaktikaks, ning kui patsient vajab pidevat ravi valu- ja põletikuvastaste ravimitega (NSAID-ravimid), siis neist põhjustatud maohaavandite profülaktikaks.
English: By blocking the pumps, pantoprazole reduces acid production.
Estonian: Prootonpumpade blokeerimisega vähendab pantoprasool maos toodetava happe kogust.
English: Pantoprazole Bluefish is a medicine used to treat diseases where the stomach produces too much acid.
Estonian: Pantoprazole Bluefishi kasutatakse selliste haiguste raviks, mille korral magu toodab liiga palju hapet.
English: The active substance in Pantoprazole Bluefish, pantoprazole, is a proton pump inhibitor.
Estonian: Pantoprazole Bluefishi toimeaine pantoprasool on prootonpumba inhibiitor.
English: Pantoprozole Bluefish is a generic medicine based on the reference medicine Pantecta.
Estonian: Pantoprozole Bluefish on geneeriline ravim, mis on välja töötatud võrdlusravimi Pantecta põhjal.
English: Pantoprazole Bluefish is presented as gastro-resistant tablets.
Estonian: Pantoprazole Bluefishi turustatakse gastroresistentsete tablettidena.
English: Questions and answers on the referral for Pantoprazole Bluefish pantoprazole 20 and 40 mg tablets
Estonian: Teave Pantoprazole Bluefish (20 mg ja 40 mg pantoprasoolitabletid) esildismenetluse kohta
English: It works by blocking ‘proton pumps', proteins found in specialised cells in the stomach lining that pump acid into the stomach.
Estonian: See blokeerib mao parietaalrakkudes leiduvad prootonpumbad (teatud valgud, mis „pumpavad” makku hapet).
English: These are tablets that pass through the stomach without being broken down until they reach the intestine.
Estonian: Need tabletid ei lagune maos, vaid alles sooles.
English: Company responses provided on: 21 September 2009, 26 October 2009 Opinion date:
Estonian: Dr Harald Enzmann (Saksamaa) Esildismenetluse alguse kuupäev: 20. august 2009 Ettevõtte vastuste kuupäevad:
English: This overview was last updated in 04-2018.
Estonian: Kokkuvõtte viimane uuendus: 04.2018.
English: Every year, the Agency will review any new information that becomes available and this summary will be updated as necessary.
Estonian: Amet vaatab igal aastal läbi kogu uue teabe ja vajaduse korral uuendab käesolevat ülevaadet.
English: Bosulif is available as tablets (100, 400 and 500 mg).
Estonian: Bosulifi turustatakse tablettidena (100, 400 ja 500 mg).
English: What measures are being taken to ensure the safe and effective use of Bosulif?
Estonian: Mis meetmed võetakse, et tagada Bosulifi ohutu ja efektiivne kasutamine?
English: Further information on Bosulif can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Bosulifi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Bosulif received a marketing authorisation valid throughout the EU on 27 March 2013.
Estonian: Bosulif on saanud müügiloa, mis kehtib kogu ELis, 27. märtsil 2013.
English: Bosulif (bosutinib)
Estonian: Bosulif (bosutiniib)
English: The side effects of the medicine are considered to be manageable.
Estonian: Ravimi kõrvalnähte peetakse hallatavateks.
English: The European Medicines Agency therefore decided that the benefits of Bosulif are greater than in its risks and recommended that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Bosulifi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The recommended dose is 400 mg once a day for newly diagnosed patients, and 500 mg once a day for patients who have already been treated with other medicines.
Estonian: Soovitatav annus on 400 mg üks kord ööpäevas esmadiagnoosiga patsientidel ja 500 mg üks kord ööpäevas patsientidel, keda on varem ravitud teiste ravimitega.
English: What is Bosulif and what is it used for?
Estonian: Mis on Bosulif ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Bosulif are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Bosulifi kasutamise kohta pidevat järelevalvet.
English: Side effects reported with Bosulif are carefully evaluated and any necessary action taken to protect patients.
Estonian: Bosulifi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The doctor may increase the dose up to 600 mg once a day or reduce it or interrupt treatment according to how the medicine is working and the side effects the patient has.
Estonian: Arst võib annust suurendada 600 mg-ni üks kord ööpäevas, annust vähendada või ravi katkestada, arvestades ravitoimet ja patsiendil tekkinud kõrvalnähte.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bosulif have been included in the summary of product characteristics and the package leaflet.
Estonian: Bosulifi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Bosulif must not be used in patients with reduced liver function.
Estonian: Bosulifi ei tohi kasutada kahjustatud maksafunktsiooniga patsiendid.
English: Other information about Bosulif
Estonian: Muu teave Bosulifi kohta
English: What are the risks associated with Bosulif?
Estonian: Mis riskid Bosulifiga kaasnevad?
English: What information is still awaited for Bosulif?
Estonian: Mis teavet Bosulifi kohta veel oodatakse?
English: Bosulif has been given ‘conditional authorisation'.
Estonian: Bosulif on saanud müügiloa tingimusliku heakskiidu alusel.
English: Effectiveness was also measured in other ways including ‘haematological response' (a return to normal of the number of white cells in the blood).
Estonian: Efektiivsust mõõdeti ka teiste meetoditega, sealhulgas hematoloogilise ravivastusega (valgete vereliblede normaalse sisalduse taastumine).
English: Bosulif was not compared with another treatment.
Estonian: Bosulifi ei võrreldud teiste ravimitega.
English: After one year of treatment, 47% (116 out of 246) of patients treated with Bosulif had a major molecular response, compared with 37% (89 out of 241) of patients treated with imatinib.
Estonian: Pärast üht raviaastat oli oluline molekulaarne ravivastus tekkinud 47%-l Bosulifi kasutanud patsientidest (116 patsienti 246st) ja 37%-l imatiniibiga ravitud patsientidest (89 patsienti 241st).
English: How does Bosulif work?
Estonian: Kuidas Bosulif toimib?
English: Bosulif has been shown to improve the condition of patients with CML, including by reducing the number of cancer cells with the Philadelphia chromosome and returning white blood cell levels to normal.
Estonian: On tõendatud, et Bosulif parandab kroonilise müeloidleukeemiaga patsientide seisundit, sealhulgas vähendades Philadelphia kromosoomiga vähirakkude arvu ja taastades valgevereliblede normaalse sisalduse.
English: For more information about using Bosulif, see the package leaflet or contact a doctor or pharmacist.
Estonian: Lisateavet Bosulifi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Bosulif treatment was effective in patients with an unmet medical need: 18 out of 36 patients with chronic phase CML had a ‘major cytogenetic response', while 7 out of the 16 patients with advanced (accelerated or blast phase) CML also had a sufficient response based on other measurements.
Estonian: Bosulif-ravi oli täitmata ravivajadusega patsientidel efektiivne: 18 kroonilises faasis haigusega patsiendil 36-st tekkis oluline tsütogeneetiline ravivastus, samas kui 7 kaugelearenenud (aktseleratsiooni- või blastses faasis) kroonilise müeloidleukeemiaga patsiendil 16-st tekkis piisav ravivastus teiste mõõtemeetodite alusel.
English: How is Bosulif used?
Estonian: Kuidas Bosulifi kasutatakse?
English: Bosulif is a cancer medicine that is used to treat chronic myeloid leukaemia (CML), a cancer of the white blood cells, in adults with a special chromosome in their cells called the Philadelphia chromosome.
Estonian: Bosulif on vähiravim, mida kasutatakse kroonilise müeloidleukeemia (teatav valgevereliblede vähk) raviks täiskasvanutel, kelle vähirakkudes on tuvastatud Philadelphia kromosoom.
English: Of these, 52 patients were considered to have an unmet medical need, because disease resistance or the risk of severe side effects made other tyrosine kinase inhibitors unsuitable.
Estonian: Nendest patsientidest 52 tuvastati täitmata ravivajadusega patsientidena, kellel ei peetud teisi türosiinkinaasiinhibiitoreid resistentsuse või raskete kõrvalnähtude riski tõttu sobivaks ravivalikuks.
English: For the full list of all side effects reported with Bosulif, see the package leaflet.
Estonian: Bosulifi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Bosulif was investigated in one main study involving 570 patients with Ph+ CML who had previously been treated with at least one tyrosine kinase inhibitor.
Estonian: Bosulifi uuriti ühes põhiuuringus, milles osales 570 Philadelphia-kromosoom-positiivse kroonilise müeloidleukeemiaga patsienti, keda oli varem ravitud vähemalt ühe türosiinkinaasiinhibiitoriga.
English: Among these patients, 36 had chronic phase CML and 16 had either accelerated or blast phase CML.
Estonian: Neist 36 patsiendi haigus oli kroonilises faasis ja 16 patsiendi haigus aktseleratsiooni- või blastses faasis.
English: For more information about treatment with Bosulif, read the package leaflet (also part of the EPAR) or contact a doctor or pharmacist.
Estonian: Kui vajate Bosulifiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The most serious side effects (which may affect more than 1 in 20 people) include thrombocytopenia, anaemia, diarrhoea, rash, neutropenia (low levels of neutrophils, a type of white blood cell) and blood tests suggesting damage to the liver and pancreas.
Estonian: Kõige raskemad kõrvalnähud (võivad esineda enam kui 1 patsiendil 20st) on trombotsütopeenia, aneemia, kõhulahtisus, lööve, neutropeenia (neutrofiilide ehk teatud valgevereliblede vähesus) ning maksa- ja pankreasekahjustusele viitavad vereanalüüsi leiud.
English: A second study in 536 newly diagnosed CML patients in the ‘chronic phase' compared Bosulif with imatinib.
Estonian: Teises uuringus, milles osales 536 kroonilises faasis kroonilise müeloidleukeemia esmadiagnoosiga patsienti, võrreldi Bosulifi imatiniibiga.
English: The main measure of effectiveness was the number of patients who had a ‘major molecular response' (where the amount in the bone marrow of BCR-ABL, the protein produced by the Philadelphia chromosome, is greatly lowered).
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis oluline molekulaarne ravivastus (Philadelphia kromosoomi toodetava valgu Bcr-Abl sisalduse oluline vähenemine luuüdis).
English: It can only be obtained with a prescription and treatment should be started by a doctor who is experienced in the diagnosis and treatment of CML.
Estonian: Ravi sellega peab alustama kroonilise müeloidleukeemia diagnoosimises ja ravis kogenud arst.
English: The most common side effects with Bosulif (which may affect more than 1 in 5 people) are diarrhoea, nausea (feeling sick), thrombocytopenia (low blood platelet counts), abdominal pain (belly ache), vomiting, rash, anaemia (low red blood cell counts), tiredness, fever and increased levels of liver enzymes.
Estonian: Bosulifi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on kõhulahtisus, iiveldus, trombotsütopeenia (trombotsüütide vähesus), kõhuvalu, oksendamine, lööve, aneemia (vere punaliblede vähesus), väsimus, palavik ja maksaensüümide aktiivsuse suurenemine.
English: An overview of Bosulif and why it is authorised in the EU
Estonian: Ülevaade ravimist Bosulif ja ELis müügiloa väljastamise põhjendus
English: The main measure of effectiveness was the number of patients who had at least a ‘major cytogenetic response' (where the proportion of white blood cells with the Philadelphia chromosome fell below 35%) after six months of Bosulif treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel tekkis pärast 6-kuulist Bosulif-ravi vähemalt oluline tsütogeneetiline ravivastus (Philadelphia kromosoomiga valgevereliblede osakaalu vähenemine alla 35%).
English: Since Bosulif has been granted a conditional approval, the company that markets Bosulif will carry out and submit the results of a larger study with Bosulif in patients with Ph+ CML previously treated with one or more tyrosine kinase inhibitors and for whom dasatinib, imatinib and nilotinib are not considered appropriate treatment options.
Estonian: Et Bosulif on saanud müügiloa tingimusliku heakskiidu alusel, korraldab Bosulifi turustaja Bosulifiga suurema uuringu, milles osalevad Philadelphia-kromosoom-positiivse kroonilise müeloidleukeemiaga patsiendid, keda on varem ravitud ühe või enama türosiinkinaasiinhibiitoriga ja kellel dasatiniibi, imatiniibi ega nilotiniibi ei loeta sobivateks ravivalikuteks, ning esitab selle uuringu tulemused.
English: By blocking their action, Bosulif helps to control cell division, thereby controlling the growth and spread of the leukaemia cells in CML.
Estonian: Nende ensüümide toime blokeerimisega aitab Bosulif reguleerida kroonilise müeloidleukeemiaga kaasnevat rakkude jagunemist ning seeläbi ka rakkude kasvu ja levikut.
English: It is used to treat three stages of CML called ‘chronic phase', ‘accelerated phase' and ‘blast phase' in patients who have already been treated with one or more tyrosine kinase inhibitors (medicines for CML which work in a similar way to Bosulif), and when the tyrosine kinase inhibitors called dasatinib, imatinib and nilotinib are not suitable.
Estonian: Seda kasutatakse kroonilises, aktseleratsiooni- ja blastses faasis kroonilise müeloidleukeemiaga patsientidel, keda on varem ravitud ühe või enama türosiinkinaasiinhibiitoriga (kroonilise müeloidleukeemia ravimid, millel on sarnane toimemehhanism nagu Bosulifil) ja kellele türosiinkinaasiinhibiitorid dasatiniib, imatiniib ja nilotiniib ei sobi.
English: Studies have shown that Bosulif is effective at reducing the proportion of white blood cells with the Philadelphia chromosome.
Estonian: Uuringutes tõendati Bosulifi efektiivsus Philadelphia kromosoomiga valgevereliblede arvu vähendamisel.
English: What benefits of Bosulif have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Bosulifi kasulikkus?
English: It blocks the action of enzymes known as Src and Bcr-Abl tyrosine kinases found on leukaemia cells where they are involved in stimulating the cells to divide uncontrollably.
Estonian: Neid ensüüme leidub leukeemiarakkude pinnal, kus need aitavad stimuleerida rakkude kontrollimatut jagunemist.
English: Bosulif is also used to treat newly diagnosed patients who are in the ‘chronic phase' of CML.
Estonian: Bosulifi kasutatakse ka kroonilises faasis kroonilise müeloidleukeemia esmadiagnoosiga patsientidel.
English: The active substance in Bosulif, bosutinib, is a tyrosine kinase inhibitor.
Estonian: Bosulifi toimeaine bosutiniib on türosiinkinaasiinhibiitor, mis blokeerib Src- ja Bcr-Abl-türosiinkinaaside (teatavad ensüümid) toime.
English: The application was at day 181 when the company withdrew.
Estonian: Taotluse menetlus oli kestnud 181 päeva, kui ettevõte võttis taotluse tagasi.
English: Pain was measured by the patients on an 11-point scale.
Estonian: Patsiendid mõõtsid valu tugevust 11-punktisel skaalal.
English: International non-proprietary name (INN): lacosamide
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): lakosamiiid
English: Ref. EMEA/522632/2008
Estonian: London, 23. oktoober 2008 Viide: EMEA/605930/2008
English: The effectiveness of three doses of Lacosamide Pain UCB Pharma (200, 400 and 600 mg per day) was compared with that of placebo (a dummy treatment) in a total of 1,724 patients in four main studies.
Estonian: Lacosamide Pain UCB Pharma kolme annuse (200 mg, 400 mg ja 600 mg päevas) efektiivsust võrreldi platseebo (näiv ravim) efektiivsusega neljas põhiuuringus kokku 1724 patsiendil.
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Estonian: Kui ettevõte on küsimustele vastanud, vaatab inimravimikomitee vastused läbi ja võib enne otsuse tegemist esitada 180. päeval täiendavaid küsimusi.
English: Together, these actions are expected to prevent abnormal electrical activity in nerve cells, reducing pain due to nerve damage.
Estonian: Need toimed koos peaksid eeldatavasti ennetama närvirakkude ebanormaalset elektrilist aktiivsust, vähendades närvikahjustusest põhjustatud valu.
English: In all four studies, the dose of Lacosamide Pain UCB Pharma was increased gradually over a few weeks before being maintained at a stable dose for 12 weeks.
Estonian: Kõigis neljas uuringus suurendati Lacosamide Pain UCB Pharma annust järk-järgult mõne nädala jooksul kuni püsiannuseni, mida manustati 12 nädala jooksul.
English: The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks on the stable dose.
Estonian: Peamiseks efektiivsuse näitajaks oli valu tugevuse muutus võrrelduna ravi alguses ja püsiannuse manustamise nelja nädala jooksul.
English: The medicine can also cause side effects affecting the heart and central nervous system (such as dizziness), which are of concern in patients with diabetes.
Estonian: Ravimiga võivad kaasneda südame ja kesknärvisüsteemiga seotud kõrvalnähud (näiteks peapööritus), mis on probleemiks diabeetilistel patsientidel.
English: After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues outstanding.
Estonian: Inimravimikomitee oli ettevõttele esitatud küsimuste vastused läbi vaadanud, kuid mõni küsimus oli veel lahendamata.
English: What is happening with Vimpat used for the treatment of epilepsy?
Estonian: Mis toimub Vimpati kasutamisel epilepsia raviks?
English: This withdrawal has no consequences on Vimpat, for which the balance of benefits and risks remains unchanged.
Estonian: Tagasivõtmine ei avalda mõju Vimpati kasutamisele nende näidustuste raviks, mille kohta on müügiluba juba antud ning mille korral jääb kasulikkuse ja riski suhe muutumatuks.
English: The exact way in which lacosamide works is still unclear, but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells.
Estonian: Lakosamiidi täpne toimemehhanism ei ole veel selge, kuid eeldatavasti vähendab ta närvirakkude vahel elektriimpulsse edastavate naatriumikanalite (närvirakkude pinna teatud poorid) aktiivsust.
English: Lacosamide Pain UCB Pharma was expected to be used in adults to treat pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes).
Estonian: Lacosamide Pain UCB Pharmat kavatseti kasutada diabeetilise perifeerse neuropaatia (jäsemete närvikahjustus, mida võib esineda diabeediga patsientidel) põhjustatud valu raviks täiskasvanutel.
English: Lacosamide has been authorised in the European Union (EU) as an anti-epileptic medicine under the trade name Vimpat since August 2008.
Estonian: Lakosamiidile anti Euroopa Liidus müügiluba epilepsiaravimina Vimpat 2008. aasta augustis.
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Lacosamide Pain UCB Pharma had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Estonian: Inimravimikomitee oli tagasivõtmise ajal seepärast arvamusel, et Lacosamide Pain UCB Pharma kasulikkus ei ole küllaldaselt tõendatud ega ületa tuvastatud riske.
English: On 25 September 2008, UCB Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults.
Estonian: 25. septembril 2008 teatas UCB Pharma S.A ametlikult inimravimikomiteele oma soovist võtta tagasi diabeetilise neuropaatilise valu raviks täiskasvanutel kasutada kavatsetud ravimi Lacosamide Pain UCB Pharma müügiloa taotlus.
English: What were the main concerns of the CHMP?
Estonian: Mis olid inimravimikomitee ettevaatlikkuse peamised põhjused?
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Lacosamide Pain UCB Pharma could not have been approved for the treatment of diabetic neuropathic pain in adults.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimikomitee esitatud küsimustele, nägi inimravimikomitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Lacosamide Pain UCB Pharmale ei või anda kasutamiseks diabeetilise neuropaatilise valu raviks täiskasvanutel müügiluba.
English: Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma
Estonian: Teave müügiloa taotluse tagasivõtmise kohta Lacosamide Pain UCB Pharma
English: What is Lacosamide Pain UCB Pharma?
Estonian: Mis on Lacosamide Pain UCB Pharma?
English: Lacosamide Pain UCB Pharma contains the active substance lacosamide.
Estonian: Lacosamide Pain UCB Pharma sisaldab toimeainena lakosamiidi.
English: Lacosamide is also thought to be involved in the development of nerve cells that have been damaged.
Estonian: Arvatakse, et lakosamiid osaleb ka kahjustatud närvirakkude taastumises.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Lacosamide Pain UCB Pharma.
Estonian: Ettevõte teatas inimravimikomiteele, et praegu Lacosamide Pain UCB Pharma kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Lacosamide Pain UCB Pharma?
Estonian: Mis on tagasivõtmise mõju praegu Lacosamide Pain UCB Pharma kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: The effects of Lacosamide Pain UCB Pharma were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Lacosamide Pain UCB Pharma toimet muude katsetega.
English: The CHMP was concerned that the studies had not shown a meaningful benefit of Lacosamide Pain UCB Pharma.
Estonian: Inimravimikomitee arvas, et Lacosamide Pain UCB Pharma kasulikkus ei ole tõendatud.
English: How is Lacosamide Pain UCB Pharma expected to work?
Estonian: Milline on Lacosamide Pain UCB Pharma eeldatav toime?
English: What was Lacosamide Pain UCB Pharma expected to be used for?
Estonian: Milleks kavatseti Lacosamide Pain UCB Pharmat kasutada?
English: Subcutaneous use pre-filled syringe 1.0 ml (150 mg/ml) 3 (3 x 1) pre-filled syringes (multipack)
Estonian: 3 (3 x 1) süstlit (hulgipakend)
English: Subcutaneous use pre-filled pen 1.0 ml (150 mg/ml) 3 (3 x 1) pre-filled pens (multipack)
Estonian: 3 (3 x 1) pensüstlit (hulgipakend)